Presentation of a case of sprue-like enteropathy secondary to olmesartan

Authors

  • Alba Rodríguez-Pérez Servicio de Medicina Interna, Hospital Universitario de Gran Canaria Doctor Negrín, Las Palmas de Gran Canaria, Spain
  • Noel Lorenzo Service de Médecine Interne et Cancerologie, Centre Hospitalier Saint-Cyr-au-Mont-d'Or, Lyon, France
  • María Luz Plaza-Pérez Servicio de Medicina Interna, Hospital Universitario de Gran Canaria Doctor Negrín, Las Palmas de Gran Canaria, Spain
  • Jerónimo Artiles-Vizcaíno Servicio de Medicina Interna, Hospital Universitario de Gran Canaria Doctor Negrín, Las Palmas de Gran Canaria, Spain
  • Saturnino Suárez-Ortega Servicio de Medicina Interna, Hospital Universitario de Gran Canaria Doctor Negrín, Las Palmas de Gran Canaria, Spain

DOI:

https://doi.org/10.32818/reccmi.a1n1a4

Keywords:

olmesartan, sprue, constitutional syndrome

Abstract

A 64-year-old male patient hospitalised because of weight loss and chronic diarrhea. He had been previously on treatment with olmesartan. Outpatient studies including complete blood and stool tests, abdominal ultrasound and CT scan were normal. The diagnosis of sprue like disease in the context of olmersatan treatment was made upon the results of endoscopies with biopsies and the good clinical response once the medication was discontinued. The patient is asymptomatic two years later.

Downloads

Download data is not yet available.

Metrics

Metrics Loading ...

References

Headstrom PD, Surawicz CM. Chronic diarrhea. Clin Gastroenterol Hepatol. 2005; 3: 734-7.

Boudet Barraca JM. Protocolo diagnóstico de la diarrea crónica. Medicine. 2016; 12(4): 197-202.

Rubio-Tapia A, Herman ML, Ludvigsson JF, Kelly DG, Mangan TF, Wu TT, Murray JA. Severe Sprue-like Enteropathy Associated With Olmesartan. Mayo Clin Proc. 2012; 87(8): 732-8.

Suárez-Ortega S, Puente-Fernández A, Santana-Báez S, Godoy-Díaz D, Miriam Serrano-Fuentes A, Sanz-Peláez O. Síndrome constitucional: entidad clínica o cajón de sastre. Rev Med Inst Mex Seguro Soc. 2013; 51(5): 532-5.

Verdú EF, Armstrong D, Murray JA. Between celiac disease and irritable bowel syndrome: the “no man’s land” of gluten sensitvity. Am J Gastroenterol. 2009; 104: 1587-94.

U.S Food and Drug Administration – Drug Safety and Availability. Comunicado de la FDA sobre la seguridad de los medicamentos: FDA aprueba cambios en la etiqueta para problemas intestinales (enteropatía similar a esprue) asociada con el medicamento olmesartán medoxomilo para la pre- sión alta. 12-7-2013.

Fernández Bañares F, Esteve M, Salas A, Alsina M, Farré C, González C, Buxeda M, Forné M, Rosinach M, Espinós JC, María Viver J. Systematic evaluation of the causes of chronic watery diarrhea with functional characteristics. Am J Gastroenterol. 2007; 102: 2520-8.

Catassi C, Fasano A. Celicac disease diagnosis: simple rules are better than complicated algorithms. Am J Med. 2010; 123: 691-3.

Wilcox C, Turner J, Green J. Systematic review: the management of chronic diarrhoea due to bile acid malabsorption. Aliment Pharmacol Ther. 2014; 39: 923-39.

Vázquez-Roque MI, Camilleri M, Smyrk T, et al. A controlled trial of gluten-free diet in irritable bowel syndrome-diarrhea: effect on bowel frequency and intestinal functions. Gastroenterology. 2013; 144: 903-11.

Miranda Díaz M, Alonso Romero L, De Castro Ochoa M, Millán Jiménez A. Sección de Gastroenterología Pediátrica. Unidad de Gestión Clínica de Pediatría y Neonatología. Hospital Universitario de Valme-Sevilla. Enfermedad celíaca: nuevos criterios diagnósticos. Vox Paediatrica. 2012; XIX(2): 28-33.

Published

2016-12-31

How to Cite

1.
Rodríguez-Pérez A, Lorenzo N, Plaza-Pérez ML, Artiles-Vizcaíno J, Suárez-Ortega S. Presentation of a case of sprue-like enteropathy secondary to olmesartan. Rev Esp Casos Clin Med Intern [Internet]. 2016 Dec. 31 [cited 2024 Dec. 26];1(1):7-9. Available from: https://www.reccmi.com/RECCMI/article/view/45